Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

• Zacks Investment Research 18 sept

  XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

  Xenon Pharmaceuticals submitted an FDA application for azetukalner to treat focal onset seizures, supported by positive phase IIb and phase III epilepsy studies showing significant seizure reductions. However, the company temporarily paused enrollment in depression studies due to neuropsychiatric adverse events, causing a 27% stock decline in premarket trading. The X-NOVA2 depression study is 80% enrolled with top-line data expected in Q1 2027.

  

• GlobeNewswire Inc. 10 jun

  Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

  The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.